Novo Nordisk’s Zenagamtide Isn’t Chasing Ozempic — It’s Trying to Make Tirzepatide Obsolete
Novo Nordisk's zenagamtide hit 14.6% weight loss and 89.1% A1C control in Phase 2. Here's what the ADA 2026...
ADA 2026
Novo Nordisk's zenagamtide hit 14.6% weight loss and 89.1% A1C control in Phase 2. Here's what the ADA 2026...